Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Hamartoma Syndrome, Multiple × Everolimus × Clear all

Phase

Phase 2/3 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 2 Autistic Disorder 2 Uterine Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Intellectual Disability 1 Hamartoma Syndrome, Multiple 1 Gastroenteropancreatic Neuroendocrine Tumors 1 Gallbladder Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07218575 2025-10-20

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Boston Children's Hospital

Phase 2/3 Not yet recruiting

Autistic Disorder, Hamartoma Syndrome, Multiple

Data powered by HemOnc (CC BY 4.0) Colophon ⚡